A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsight

0

Los Angeles, June 08, 2021 (GLOBE NEWSWIRE) — A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsight

For the treatment of Chronic Spontaneous Urticaria, there are several drugs being developed by different pharmaceutical industries with different routes of administration like oral, subcutaneous, intravenous which could be chosen according to the affordability and feasibility of an individual.

DelveInsight’s Chronic Spontaneous Urticaria Pipeline Insights report offers a holistic coverage of the current treatments and pipeline therapies and landscape in different stages of development from pre-clinical till late-stage, along with dormant, inactive and abandoned therapeutic agents. 

Some of the key pointers from the Chronic Spontaneous Urticaria Pipeline report:

  • Chronic Spontaneous Urticaria Pipeline report offers a rich analysis of  18+ key players actively working in the space developing over  18+ key therapies. 
  • Chronic Spontaneous Urticaria pipeline comprises therapies in different stages of trials such as UB-221, GBR 310, Ligelizumab, UCB8600, Antolimab, Dupilumab, GI-301, CDX-0159, LY3454738, among others. 
  • Key pharma companies involved in accelerating the drug development for Chronic Spontaneous Urticaria include Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, GlaxoSmithKline, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, among others. 
  • DelveInsight estimates that Ligelizumab, a next-generation high-affinity humanized monoclonal anti-IgE antibody is expected to emerge as a potential therapeutic agent owing to the treatment.
  • Celltrion has initiated the clinical trials of its CT-P39, a biosimilar of omalizumab (Xolair), to Phase 3 trials in November 2020.
  • United BioPharma obtained Taiwan FDA approval for conducting a phase I clinical trial of its UB21 product, a third-generation monoclonal anti-IgE antibody and initiated a phase I clinical trial in May 2020.
  • The U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of Chronic Spontaneous Urticaria (CSU) in patients who have an inadequate response to H1-antihistamine treatment.
  • Tezepelumab is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being developed and investigated for the treatment of Chronic Spontaneous Urticaria (CSU) by Amgen in collaboration with AstraZeneca.
  • Celldex Therapeutics has initiated Phase 1b studies of CDX-0159 in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU), both mast cell-related diseases, in the fall of 2020.
  • Lirentelimab (AK002) being developed by Allakos, targets Siglec-8, an inhibitory receptor found on the surface of mast cells and eosinophils. Allakos has completed an open-label Phase 2a clinical trial evaluating lirentelimab in patients with multiple forms of Chronic Urticaria. 

Request for Sample to know more about the key pharma company and therapy expected to grab maximum share @ Chronic Spontaneous Urticaria Emerging Therapies and Forecast 

Chronic Spontaneous Urticaria: Overview

Chronic Urticaria (CU) is a condition of the skin caused by a plenitude of factors such as environmental irritants, your immune system, genetics, or in response to a bacterial, fungal, or viral infection. Based on the cause, it can be of two types Chronic Idiopathic Urticaria (also called chronic spontaneous urticaria) and Chronic Inducible Urticaria (also called physical urticaria). 

Chronic Spontaneous Urticaria was previously referred to as Chronic Idiopathic Urticaria, however, the term is no longer used as many cases have an autoimmune basis.

For more information on emerging drugs, visit Chronic Spontaneous Urticaria Pipeline Analysis 

Chronic Spontaneous Urticaria Drug Pipeline Assessment

Drug Company Phase MoA RoA
UB-221 United BioPharma I IgE receptor antagonists; Immunomodulators Intravenous
GBR 310 Glenmark Pharmaceuticals II IgE receptor antagonists; Immunosuppressants Subcutaneous
Ligelizumab Novartis  III IgE receptor antagonists Subcutaneous
UCB8600 UCB Biopharma NA Oral
Antolimab Allakos  II Antibody-dependent cell cytotoxicity; Immunomodulators; Mast cell inhibitors Intravenous
Dupilumab Regeneron/Sanofi III Interleukin 13 inhibitors; Interleukin 4 inhibitors Subcutaneous
GI-301 GI Innovation/Yuhan Preclinical Free IgE suppression Parenteral
CDX-0159 Celldex Therapeutics I KIT Inhibitor Subcutaneous
 LY3454738 Eli Lilly and Company II CD200R1 protein stimulants Intravenous
Fenebrutinib Genentech II Bruton’s tyrosine kinase inhibitor Oral
GS-4059 Gilead sciences II Agammaglobulinaemia tyrosine kinase inhibitors Oral
Tezepelumab Amgen II Thymic stromal lymphopoietin inhibitors Subcutaneous

Request for Sample to know more @ Chronic Spontaneous Urticaria Pipeline Analysis, Key Companies and Futuristic Trends 

Chronic Spontaneous Urticaria Therapeutics Assessment 

The Chronic Spontaneous Urticaria Pipeline report proffers comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

By Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

By Mechanism of Action

  • IgE receptor antagonists
  • Mast cell inhibitors
  • Interleukin 13 inhibitors
  • KIT Inhibitor
  • Free IgE suppression
  • Thymic stromal lymphopoietin inhibitors
  • Agammaglobulinaemia tyrosine kinase inhibitors
  • CD200R1 protein stimulants
  • Antibody-dependent cell cytotoxicity; Immunomodulators

By Targets

  • Proteins
  • Immunoglobulin
  • Interleukins

Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions 

Scope of the Chronic Spontaneous Urticaria Pipeline Report

Coverage: Global
Key Players: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, GlaxoSmithKline, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, Amgen, and others. 
Key Chronic Spontaneous Urticaria Pipeline Therapies: UB-221, GBR 310, Ligelizumab, UCB8600, Antolimab, Dupilumab, GI-301, CDX-0159, LY3454738, Fenebrutinib, GS-4059, Nucala, SYN008, BP001, Tezepelumab and others.  

Reach out @ Chronic Spontaneous Urticaria Pipeline: Novel therapies and Emerging technologies 

Table of Contents 

1 Report Introduction
2 Chronic Spontaneous Urticaria Disease Overview
3 Chronic Spontaneous Urticaria Pipeline Therapeutics
4 Therapeutic Assessment
5 Chronic Spontaneous Urticaria – DelveInsight’s Analytical Perspective
6 In-depth Commercial Assessment
7 Chronic Spontaneous Urticaria Collaboration Deals
8 Chronic Spontaneous Urticaria Therapeutic Products in Clinical Stage
9 Chronic Spontaneous Urticaria Therapeutic Products in Non-clinical Stage
10 Chronic Spontaneous Urticaria Therapeutics Pipeline Analysis
11 Inactive Chronic Spontaneous Urticaria Pipeline Products 
12 Chronic Spontaneous Urticaria Key Companies
13 Chronic Spontaneous Urticaria Key Products
14 Chronic Spontaneous Urticaria- Unmet Needs
15 Appendix
16  Report Methodology
17 Consulting Services
18 Disclaimer
19 About DelveInsight

Learn more about the report offerings @ Chronic Spontaneous Urticaria Emerging Therapies, Treatments and Ongoing Clinical Trials 

Related Reports

Chronic Spontaneous Urticaria Market
DelveInsight’s ‘Chronic spontaneous urticaria (CSU) – Market Insights, Epidemiology, and Market Forecast—2030’ report. 

Chronic Inducible Urticaria Market Forecast
DelveInsight’s ‘Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast-2030’ report.

Scleroderma Market
DelveInsight’s ” Scleroderma Market Insights, Epidemiology, and Market Forecast-2030″ report.

Skin Neoplasms Market
DelveInsight’s “Skin Neoplasms – Market Insights, Epidemiology, and Market Forecast-2030” report.

Soft Tissue Defect Market
DelveInsight’s “Soft Tissue Defect – Market Insights, Epidemiology, and Market Forecast-2030” report.

Uremic Pruritus Market
DelveInsight’s “Uremic Pruritus (UP) – Market Insights, Epidemiology, and Market Forecast-2030” report.

Warts Market
DelveInsight’s “Warts Market Insights, Epidemiology, and Market Forecast-2030” report.

Related Posts 

Highlights from ASCO2021
8 most common allergens
Deadliest infectious diseases
Chronic Hand Eczema Market Analysis and Forecast

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

Loading...

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Loading...
Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
Leave a comment